IP-001

Combination of MWA and IP001 enhances tumor suppression in an orthotopic HCC rat model. The tumor suppression is associated to the enhanced immune responses in terms of recruiting the important cell subpopulations such as CD8 + T-cells and NK cells into tumor microenvironment and abolishing immune suppressor such as Treg cells.

P1/2, N=44, Recruiting, Immunophotonics, Inc. | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

P1/2, N=44, Recruiting, Immunophotonics, Inc. | Phase classification: P1b/2a --> P1/2

P1/2, N=39, Recruiting, Swiss Group for Clinical Cancer Research | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2025

Introduction: : Immunosuppression within the tumor microenvironment of hepatocellular carcinoma (HCC) has made immune checkpoints attractive targets for therapy, however they have failed to improve overall survival (OS) as first-line monotherapy compared to sorafenib. A combination of IP-001 and MWA in an HCC Murine model led to significant increase in macrophages (CD11b + cells) dendritic cells (CD11b + CD 103 + cells), NK cells (CD 161 + cells), significant upregulation of interferon gamma, and improvement in T helper cells. Learning Objectives: Understand the combination effects of thermal ablation and N‐dihydrogalactochitosan injection Understand the immunomodulatory effects of MWA alone and in combination with N‐dihydrogalactochitosan injection Understand the HCC animal effects and immune profile that can be seen after ablation

P1/2, N=39, Not yet recruiting, Swiss Group for Clinical Cancer Research | Initiation date: Mar 2020 --> Jun 2020

P1/2, N=39, Not yet recruiting, Swiss Group for Clinical Cancer Research | Initiation date: Dec 2019 --> Mar 2020